Oral Iron for the Management of Iron Deficiency Anemia in SGLT2i-Treated Heart Failure Patients
Oral Iron for the Management of Iron Deficiency Anemia in SGLT2i-Treated Heart Failure Patients: A Prospective Analysis
People with heart failure often have anemia caused by low iron levels. Ongoing inflammation in heart failure can impair iron absorption, making oral iron therapy less effective.
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are medications used to treat heart failure. In addition to their cardiovascular benefits, these drugs may improve iron metabolism and support red blood cell production.
This study evaluates whether patients with heart failure and iron deficiency anemia who are receiving SGLT2i therapy respond to treatment with oral iron. Participants receive oral iron for three to four months, followed by a short period without treatment. Blood tests are used to assess changes in hemoglobin levels.
The objective of this study is to determine whether treatment with SGLT2i enhances the response to oral iron in patients with heart failure and iron deficiency anemia.
研究概览
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Porto、葡萄牙、4200-319
- Unidade Local de Saúde São João
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- 1) Previous diagnosis of heart failure, irrespective of ejection fraction;
- 2) Iron deficiency anemia defined as hemoglobin <13 g/dL in men or <12 g/dL in women, with transferrin saturation (TSAT) <20%;
- 3) Ongoing treatment with an SGLT2 inhibitor (SGLT2i) for more than 3 months at the time of enrollment.
Exclusion Criteria:
- 1) Concomitant use of intravenous iron, erythropoiesis-stimulating agents (ESAs), red blood cell transfusions, or other blood products within 3 months before enrollment;
- 2) Severe anemia, defined as hemoglobin <7 g/dL or clinical indication for transfusion;
- 3) Relevant intercurrent illnesses associated with inflammatory response (e.g., infection, acute kidney injury, or acute decompensated heart failure) within 3 months before enrollment;
- 4) Confirmed or suspected active bleeding;
- 5) End-stage renal disease or receiving renal replacement therapy;
- 6) History of any type of active cancer;
- 7) History of solid or non-solid organ transplantation.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Oral iron supplementation
either hydroxide polymaltose [Ferrum Haussman®] or ferrous sulfate [Ferro Gradumet®] |
Oral iron supplementation administered at the treating physician's discretion
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Hemoglobin Levels
大体时间:Baseline, 3-4 months, and 5-6 months
|
Change from baseline in hemoglobin levels measured by laboratory blood tests |
Baseline, 3-4 months, and 5-6 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Hematocrit
大体时间:Baseline, 3-4 months, and 5-6 months
|
Change from baseline in hematocrit measured by laboratory blood tests |
Baseline, 3-4 months, and 5-6 months
|
|
Change in Transferrin Saturation
大体时间:Baseline, 3-4 months, and 5-6 months
|
Change from baseline in transferrin saturation measured by laboratory blood tests. |
Baseline, 3-4 months, and 5-6 months
|
|
Change in Serum Iron
大体时间:Baseline, 3-4 months, and 5-6 months
|
Change from baseline in serum iron measured by laboratory blood tests. |
Baseline, 3-4 months, and 5-6 months
|
|
Change in Ferritin
大体时间:Baseline, 3-4 months, and 5-6 months
|
Change from baseline in ferritin measured by laboratory blood tests. |
Baseline, 3-4 months, and 5-6 months
|
|
Change in Total Iron-Binding Capacity (TIBC)
大体时间:Baseline, 3-4 months, and 5-6 months
|
Change from baseline in TIBC measured by laboratory blood tests. |
Baseline, 3-4 months, and 5-6 months
|
合作者和调查者
调查人员
- 研究主任:João P. Ferreira, PhD. MD.、Universidade do Porto
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.